Viking’s GLP-1/GIP re­cep­tor ag­o­nist helped pa­tients lose al­most 15% of their body weight over 13 weeks

Viking Ther­a­peu­tics’ dual GLP-1/GIP re­cep­tor ag­o­nist for obe­si­ty showed off pos­i­tive topline da­ta from a Phase II study, with an­a­lysts de­scrib­ing the drug as a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER